Skip to content Skip to footer
Subscribe Now
Viewpoints_Wehkamp Shares
VIEWPOINTS

PharmaShots Interview: Janssen’s Jan Wehkamp Shares Insight on the Data of Stelara (ustekinumab) for IBD and other Approved Indications and Presented 13 Abstracts at UEGW

In an interview with PharmaShots, Jan Wehkamp, M.D., Vice President, Gastroenterology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development shared his views on the data from 13 P-II & III studies of Stelara (ustekinumab) for the treatment of IBD and other approved indications Shots: The company has reported the data from 13 P-II & III studies, including 6 studies…
November 24, 2021

Read more

Viewpoints_Jan Wehkamp
VIEWPOINTS

PharmaShots Interview: Janssen’s Jan Wehkamp Shares Insight on the Data from UNIFI Study of Stelara Presented at ECCO

In an interview with PharmaShots, Jan Wehkamp, M.D., Vice President, Disease Area Leader, Gastroenterology at Janssen Research & Development shared his views on the data regarding the safety & efficacy of Stelara (ustekinumab) for UC patients, including long-term symptomatic & corticosteroid-free remission rates from the UNIFI study. Shots: The P-III UNIFI study evaluates the safety & efficacy…
August 9, 2021

Read more

Viewpoints_Dr. Jan Wehkamp and Dr. Bruce Sands
VIEWPOINTS

PharmaShots Interview: Janssen’s Dr. Jan Wehkamp and Icahn School of Medicine’s Dr. Bruce Sands Share Insights on the Data Presented at DDW 2021

In an interview with PharmaShots, Dr. Jan Wehkamp, M.D., Vice President, Gastroenterology Disease Area Leader at Janssen, and Bruce Sands, Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine share their views on the data of Stelara and Tremfya presented at DDW 2021. Shots: Janssen presented the new data on Stelara (ustekinumab) and…
July 2, 2021

Read more